Deficiency of Mbd2 suppresses intestinal tumorigenesis
- 5 May 2003
- journal article
- research article
- Published by Springer Nature in Nature Genetics
- Vol. 34 (2) , 145-147
- https://doi.org/10.1038/ng1155
Abstract
Gene silencing through de novo methylation of CpG island promoters contributes to cancer. We find that Mbd2, which recruits co-repressor complexes to methylated DNA, is essential for efficient tumorigenesis in the mouse intestine. As Mbd2-deficient mice are viable and fertile, their resistance to intestinal cancer may be of therapeutic relevance.Keywords
This publication has 11 references indexed in Scilit:
- Gene Silencing Quantitatively Controls the Function of a Developmental trans-ActivatorMolecular Cell, 2002
- MeCP2 and MBD2 expression during normal and pathological growth of the human mammary glandOncogene, 2002
- Dynamic Reprogramming of DNA Methylation in the Early Mouse EmbryoDevelopmental Biology, 2002
- Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasiaProceedings of the National Academy of Sciences, 2001
- Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse developmentGenes & Development, 2001
- MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complexNature Genetics, 1999
- A mammalian protein with specific demethylase activity for mCpG DNANature, 1999
- Suppression of intestinal neoplasia by DNA hypomethylationCell, 1995
- Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouseCell, 1993
- Multiple Intestinal Neoplasia Caused by a Mutation in the Murine Homolog of the APC GeneScience, 1992